COMMUNIQUÉS West-GlobeNewswire

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

21/01/2025 - 15:05

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ® ) with the potential to [...]

Yerbae Expands Midwest Convenience Store Presence with Casey's General Stores Authorization

21/01/2025 - 15:03

SCOTTSDALE, Ariz., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, today announced a significant expansion of [...]

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

21/01/2025 - 15:00

PALO ALTO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid [...]

Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa

21/01/2025 - 15:00

FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by [...]

Olympia Pharmaceuticals Expands into Alabama with New Licensing, Bringing GLP-1s and More to Healthcare Providers

21/01/2025 - 15:00

Nation’s leading compound pharmacy is now available in 48 states ORLANDO, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility, is [...]

Welcoming Victor Bornsztejn as Senior Vice President of Commercial

21/01/2025 - 15:00

SAN FRANCISCO, CALIFORNIA, UNITED STATES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocessing technologies, is pleased to announce the appointment of Victor Bornsztejn as the [...]

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

21/01/2025 - 15:00

GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]

Completion of Offering and Increase in Registered Capital

21/01/2025 - 15:00

TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO [...]

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

21/01/2025 - 14:30

- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. ( [...]

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

21/01/2025 - 14:30

Study showed online screening tool and patient education improved genetic testing completion rate SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and [...]

Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta

21/01/2025 - 14:30

Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant improvement over available treatments for serious conditions REDWOOD CITY, Calif., Jan. 21, 2025 [...]

Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network

21/01/2025 - 14:30

SAN FRANCISCO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adaptive Research Inc. announced that Prodigy Psychiatric Group has joined its clinical trial network, marking Adaptive Research's expansion into psychiatric research. [...]

Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology

21/01/2025 - 14:30

Thursday, January 23rd, 2025 at 4:15pm Eastern Time WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, [...]

Publication relating to transparency notifications

20/01/2025 - 22:30

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), January 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]

Publication relative à des notifications de transparence

20/01/2025 - 22:30

INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 20 janvier 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

20/01/2025 - 17:45

Saint-Herblain (France), January 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus [...]

Valneva annonce une réponse immunitaire robuste et durable chez les adolescents un an après une seule vaccination avec son vaccin contre le chikungunya

20/01/2025 - 17:45

Saint-Herblain (France), le 20 janvier 2025 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui de nouveaux résultats de Phase 3 positifs chez les adolescents [...]

ProDentim: The Breakthrough Oral Probiotic—Why ProDentim Is an Essential Dental Health Solution for 2025

20/01/2025 - 17:06

AKRON, Ohio, Jan. 20, 2025 (GLOBE NEWSWIRE) -- ProDentim enters the spotlight at a time when more individuals are rethinking conventional dental products, questioning the long-standing reliance on abrasive chemicals and [...]

Novo Nordisk A/S - share repurchase programme

20/01/2025 - 15:32

Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]